Localized NF-κB Inhibition Reduces Lipid Nanoparticle-Associated Inflammation - PubMed
8 hours ago
- #lipid nanoparticles
- #immunomodulation
- #NF-κB inhibition
- Lipid nanoparticles (LNPs) cause acute inflammation after administration, known as LAI, which limits their use for nucleic acid delivery.
- Inhibiting NF-κB, a key inflammation mediator, is promising for reducing LAI, but systemic inhibition risks immunosuppression, requiring localized approaches.
- Researchers screened NF-κB inhibitors that load into LNPs, reduce inflammation in vitro and in vivo, and maintain mRNA cargo expression in target tissues.
- Co-formulating NF-κB inhibitors with nucleic acids in LNPs enables localized immunomodulation, improving safety for inflammatory or high-risk patients.